A multicentre clinical trial protocol outlines a new phase II platform design to evaluate targeted monotherapy and combination treatments for patients facing relapsed or refractory primary central nervous system lymphoma. The open-label study, designated PRiZM+, establishes sequential treatment arms to determine whether newer therapeutic regimens show sufficient clinical activity to justify testing in subsequent randomised controlled trials. Primary central nervous system lymphoma represents an aggressive malignancy originating within the brain or spinal cord, where disease relapse or resistance to upfront therapy remains common and confers an exceptionally poor prognosis.
The study protocol addresses an urgent clinical requirement for effective interventions capable of prolonging survival while limiting treatment-related toxicities in vulnerable individuals. Previous clinical evidence has confirmed that inhibiting Bruton tyrosine kinase yields measurable activity against relapsed and refractory primary central nervous system lymphoma. Furthermore, systemic large B-cell lymphoma trials have demonstrated the therapeutic efficacy of pairing the CD19-directed agent tafasitamab with the immunomodulatory drug lenalidomide, providing a clear rationale for testing related regimens within central nervous system disease.
Under the trial framework, investigators plan to recruit sequential cohorts of twenty participants across a coordinated network of specialised medical centres. Key participant eligibility mandates a confirmed diagnosis of CD20-positive large B-cell lymphoma strictly confined to the central nervous system. Candidates must exhibit relapsed or refractory disease following completion of at least one cycle of high-dose methotrexate therapy, present with measurable lesions on magnetic resonance imaging, and have no prior exposure to the specific experimental drug classes being assessed.
To ensure broader applicability and reflect the true clinical population, the protocol permits the enrollment of individuals presenting with impaired baseline functional status or disease-related cognitive dysfunction. The primary outcome measure is defined as the overall response rate determined by local magnetic resonance imaging assessments following two complete treatment cycles.
Participants entering the initial treatment cohort will receive zanubrutinib monotherapy at a dose of 160 milligrams twice daily in continuous 28-day cycles. For the subsequent cohort, researchers plan to evaluate the combination of continuous zanubrutinib with twelve cycles of tafasitamab and lenalidomide. Within this combination regimen, tafasitamab will be administered at weekly then fortnightly doses of 12 milligrams per kilogram, alongside 25 milligrams daily of lenalidomide from days 1 to 21.
Assigned study treatments are scheduled to proceed continuously until the occurrence of confirmed disease progression, unacceptable drug toxicities, or voluntary patient withdrawal. To evaluate therapeutic merit rapidly, investigators will deploy Bayesian statistical models to calculate the probability that the true overall response rate for each sequential experimental arm is high enough to justify formal randomised investigation.
The trial protocol incorporates multiple translational sub-studies designed to advance scientific understanding of lymphoma biology and inform future therapeutic approaches. Exploratory endpoints will assess drug pharmacokinetics, genomic profiles, transcriptomic characteristics, and molecular or radiological correlates of clinical response. By coordinating multiple experimental regimens under a single master platform, the PRiZM+ trial aims to accelerate therapeutic discovery within a critical area of unmet neuro-oncology need.
The operational efficiency of the PRiZM+ trial relies heavily on its overarching master protocol, which enables the research team to evaluate multiple sequential regimens across an established network of expert clinical sites.
By explicitly structuring eligibility and testing schedules to accommodate neurological impairments, the investigators ensure that trial enrollment reflects real-world clinical presentations while maintaining the analytical validity of the recorded outcomes. The platform trial has been formally registered under the identifier ISRCTN90634455, marking an organized effort to deliver systematic evidence for relapsed and refractory central nervous system lymphoma.
Subject of Research: Clinical trial protocol evaluating zanubrutinib monotherapy and combination therapy in relapsed or refractory primary central nervous system lymphoma
Article Title: Zanubrutinib monotherapy and combination therapy for relapsed and refractory primary CNS lymphoma (PRiZM+): study protocol for a multi-centre, open-label, Bayesian phase II platform trial
Article References: McIlroy, G., Yates, F., Maycock, S., Howarth, D., Homer, E., Collings, R., Fox, S., Boucher, R., Thust, S., Khwaja, J., Martinez-Calle, N., Phillips, E. H., Smith, J., Jackson, A., Auer, D., Okosun, J., Cwynarski, K., & Fox, C. P. (2026). Zanubrutinib monotherapy and combination therapy for relapsed and refractory primary CNS lymphoma (PRiZM+): study protocol for a multi-centre, open-label, Bayesian phase II platform trial. BMC Cancer. https://doi.org/10.1186/s12885-026-17090-z
Image Credits: AI Generated
DOI: 10.1186/s12885-026-17090-z
Keywords: primary central nervous system lymphoma, rrPCNSL, zanubrutinib, tafasitamab, lenalidomide, Bruton tyrosine kinase inhibitor, phase II trial, platform trial, Bayesian statistics, clinical trial protocol, overall response rate, high-dose methotrexate, CD20-positive lymphoma, neuro-oncology, brain malignancy, targeted therapy, immunomodulation
News Source: Nathaniel Bowman. (November 13, 2026). Bayesian Phase II Platform Trial Tests Novel Targeted Regimens for Brain Lymphoma. Scienmag.



